We are live on ! Find out more

Lexaria Bioscience

LEXX

Market cap $9.48M

4.50 USD

+0.33

7.91%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

4.33

-0.17

3.78%

1 day

7.91%

5 days

28.57%

1 month

38.89%

3 months

-15.73%

6 months

-55.53%

Year to date

-54.13%

1 year

-72.22%

5 years

-95.31%

10 years

-93.3%

About: Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Employees: 7

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.7%

Neutral 92.3%

Negative 0%

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Third pharmaceutical company relationship entered Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical company (“ PharmCo ”) to investigate Lexaria's DehydraTECH technology with one or more proprietary PharmCo molecules.

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Lexaria Celebrates its 70th Patent Award

New patents awarded in the US, Canada, and Europe IP protection for treatments for Epilepsy, Diabetes, and Hypertension

Lexaria Celebrates its 70th Patent Award

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® commercially available Wegovy® tablets, over a 5-week duration (the "Study"). The final Study arm was fully enrolled and began dosing, as scheduled, in early October.

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Lexaria Announces Results from Animal Study GLP-1-A26-1

Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation enhancements using both DehydraTECH-CBD ("DHT-CBD") compositions and DehydraTECH-semaglutide ("DHT-SEMA") glucagon-like peptide-1 ("GLP-1") compositions to explore the potential for additional improved performance, as well as stake new intellectual property ("IP") claims. Lexaria has already filed 3 new patent applications related to the formulations evaluated in this Study to protect this new IP.

Lexaria Announces Results from Animal Study GLP-1-A26-1

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Lexaria Updates Financial Position

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update. Lexaria is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at US$12.92/share.

Lexaria Updates Financial Position

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85 per share, at a reduced exercise price of $12.92 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds

Kelowna, British Columbia – TheNewswire - September 8 , 2026 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85 per share, at a reduced exercise price of $12.92 per share. The closing of the warrant exercise transaction is expected to occur on or about September 9, 2026, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering .

Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kelowna, British Columbia – September 4 , 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 th through September 16 th , 2026 in New York City. Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link .

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate Kelowna, British Columbia – September 1 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Lexaria Receives USD$2.6 Million Tax Rebate Payment

See News Rankings

Price charts implemented using Lightweight Charts™